Modality
Radioligand
MOA
FGFRi
Target
Tau
Pathway
Epigenetic
PBC
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Oct 2030
Phase 2Current
NCT04623840
2,503 pts·PBC
2022-08→2030-10·Active
2,503 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-154.5y awayPh3 Readout· PBC
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
Catalysts
Ph3 Readout
2030-10-15 · 4.5y away
PBC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04623840 | Phase 2/3 | PBC | Active | 2503 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 | |
| Capirelsin | Y-mAbs | Phase 2 | FLT3 |